Background Prostate cancer is one of the leading causes of death from malignant disease among men in the developed world. One strategy to decrease the risk of death from this disease is screening with prostate-specifi c antigen (PSA); however, the extent of benefi t and harm with such screening is under continuous debate.
Introduction
The European Randomised Study of Screening for Prostate Cancer (ERSPC) compared a group of men invited for prostate-cancer screening based on prostatespecifi c antigen (PSA) with a control group without any active intervention. Interim analyses, based on a median follow-up of 9 years, 1, 2 showed that men randomised to active screening had a signifi cant reduction in prostatecancer mortality; rate ratio (RR) 0·80 (95% CI 0·65-0·98, adjusted p=0·04). 1 The number of men needed to be screened (NNS) to prevent one death from prostate cancer was 1410 (or 1068 in men who were actually screened 1 ), which is similar to breast and colorectal cancer screening. [3] [4] [5] [6] However, the number of men needed to treat (NNT) to prevent one death was high (48 men), which might be explained by only 9 years of follow-up or by screening that resulted in the detection of a large proportion of indolent cancers.
These reports provide the fi rst level one evidence that PSA-based prostate-cancer screening can reduce prostatecancer mortality. An open question, however, is whether the modest benefi t in reduced cancer mortality documented thus far outweighs the harms of overdetection. This issue is emphasised by the report from another large screening trial, the US-based Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial, which found no diff erence in prostate-cancer mortality between men randomised to screening and those in the control group at 11·5 years of follow-up. 7 Other randomised studies have either been too small 8, 9 or criticised for methodological problems. 10, 11 The Göteborg randomised population-based prostatecancer screening trial is a prospective randomised trial, planned and started in 1995, assessing the eff ects of PSA-based screening every 2 years. The trial is truly population-based, as individuals from the population register were randomised to screening or control groups without prior information, which results in a more representative study than randomisation after informed consent. The study design allows the analysis of both how a screening programme will be accepted by the population and its eff ectiveness in terms of prostatecancer mortality reduction at a population level. The trial was designed and initiated independently from the ERSPC, although it was subsequently agreed to include a subset of participants in the ERSPC. According to the ethical committee approval from 1994, an analysis of this study was planned for after 15 years. The present report is the fi rst publication from the Göteborg trial assessing prostate-cancer mortality.
Methods

Participants
As of Dec 31, 1994 , the population register documented 32 298 men born between 1930 and 1944 (age 50-64, median 56 years) living in the city of Göteborg, Sweden. By computer randomisation 20 000 of these men were identifi ed and allocated to either the intervention arm (screening group) or to a control group. The number of men in each birth cohort (1930-34, 1935-39, and 1940-44 ) was calculated to be proportional to the distribution in the original cohort. This resulted in larger birth cohorts from the 1940s than those from the early 1930s. The ethical review committee at the University of Göteborg approved this study in 1994.
Randomisation and masking
The randomisation procedure was done at the Department of Statistics at the University of Göteborg. 10-digit personal identifi ers were the only available personal data for those doing the computer randomisation. No informed consent was needed from those in the control group. Masking of the group assignment was only done for the cause of death committee. However, possible discrepancies, caused by group assignments, were analysed for diff erences in the treatments given.
Procedures
Invitations to screening began in January, 1995, and in 1996 the study became associated with the ERSPC without any changes in the protocol. Results from the men born between 1930 and 1939 have been published within the previous ERSPC report. 1 Men allocated to the screening group were invited for PSA testing every second year, until they reached the upper age limit; 12 the mean age at last invitation to screening was 69 years (67-71). The written invitation informed men about the study design, the complexity of PSA screening, and the voluntary nature of participation. Blood was processed within 3 h of venipuncture, frozen, and shipped frozen on dry ice for analyses within 2 weeks of the blood draw. Total PSA was measured using duallabel DELFIA Prostatus total/free PSA-assay (PerkinElmer, Turku, Finland). Calibration of this assay changed in 2004 to refl ect the WHO 96/670 calibrator; 13,14 a correction factor was applied to the earlier measurements, and all fi gures given in this paper are in accordance with this calibration.
The PSA threshold needed to invite men to further urological work-up was 3·4 ng/mL (WHO corrected value; the nominal value was 3·0 ng/mL) between 1995 and 1998; in 1999 the threshold was changed to 2·9 ng/mL (nominal value 2·5 ng/mL) for consistency with other ERSPC sites. Due to the change of assay-calibrator, the threshold changed again to 2·5 ng/mL at the start of 2005.
Men with PSA below the threshold did not have further assessment, but were invited again after 2 years. Only men with PSA at or above the threshold were invited for further urological work-up, which included digital rectal examination (DRE), trans-rectal ultrasound (TRUS) examination, and laterally directed sextant biopsies. For men diagnosed with prostate cancer, the protocol did not specify any particular treatment; further evaluation and treatment was at the discretion of their physicians. Men with a benign fi nding at biopsy were invited for screening again after 2 years. Men with persistently raised PSA concentrations were recommended to have a new prostate biopsy at each visit at which PSA was raised. Seven screening rounds were completed by the end of 2008. Minor changes in the screening algorithm have been made during the study period. 15 In both arms of the study, the incidence of prostate cancer was checked by linking with the West Swedish COD for men diagnosed with prostate cancer was determined by an independent COD committee. The committee did a blinded review of all cases diagnosed with prostate cancer, including all medical records, pathology reports, and autopsy protocols, according to a standard algorithm used in the ERSPC. 16 The COD certifi cates were not available to the COD committee. Deaths classifi ed as defi nitive prostate-cancer deaths, intervention-related deaths (ie, deaths from diagnostic procedures or treatment), or probable prostate-cancer deaths were regarded as deaths caused by prostate cancer, whereas other classifi cations were regarded as nonprostate cancer deaths.
Statistical analysis
The main outcome measures were absolute and relativerisk reduction in cumulative prostate-cancer mortality between study arms. Secondary measures were the cumulative prostate-cancer incidence and the proportion of screening attendees. A pre-study power calculation (two-sided test; p<0·05 and 80% power) was done with the assumption of a 70% participation rate. A 40% mortality diff erence between the study arms was calculated to become signifi cant 15 years after the study began (Dec 31, 2009). A new power calculation in 2009 incorporated the observed 76% participation rate in the Swedish branch of the published ERSPC results; 1 the new calculation suggested that the study has suffi cient power to allow analyses to be done a year early.
Cumulative incidences of prostate cancer in the screening and control groups were plotted as 1 minus the KaplanMeier estimator. The corresponding hazard ratio (HR) for the incidence of prostate cancer between the groups was estimated by Cox regression and the proportional hazard assumption was tested with Schoenfeld residuals. 17 A timedependent covariate approach was used to estimate the HR at diff erent time periods after the start of screening to avoid violation of the proportional hazard assumption. The Nelson-Aalen method was used to calculate the cumulative hazard for prostate-cancer mortality. 18 Poisson-regression analysis was used to estimate the mortality-rate ratio in the screening group versus the control group. All p values were two-sided. NNS was calculated as 1 divided by absolute reduction in prostate-cancer mortality. As this study is an intention-to-screen analysis, we refer to NNS as the number needed to invite for screening. The NNT was calculated as 1 divided by (absolute reduction in prostatecancer mortality multiplied by excess prostate-cancer incidence); we renamed this measure as number needed PSA=prostate-specifi c antigen. PC=prostate cancer. *The low attendance rate in the third invitation round was because men with total PSA<1 ng/mL in the second invitation round were not invited (except those born 1930-31). †The total number of PSA tests done in the study. ‡The total number of PSA tests exceeding the PSA cutoff during the study. Table : Number and outcome of participants in relation to screening visit to diagnose, because many patients were not actually treated. The analyses were done using Stata, release 11. This study is registered with controlled-trials.com, number ISRCTN54449243.
Role of the funding source
The funding sources had no role in the study design and conduct, collection, management, analysis, and interpretation of the data, or writing of the report. The funding sources had no access to the database, which is kept at the Sahlgrenska University Hospital. All authors of this manuscript have had full access to the database. JH had the fi nal responsibility to submit the paper for publication.
Results
The trial profi le is shown in fi gure 1. Subsequent to randomisation, we excluded from analysis 56 men with a prior diagnosis of prostate cancer, 34 who had died, and six who had emigrated but had not been removed from the population register at the time of randomisation. Thus, the screening and control groups each consisted of 9952 evaluable men. In the screening group, 7578 (76%) of 9952 men participated in at least one screening round (attendees; (table 2) . Of those men with detected prostate cancer in the screening group, 896 (78·7%) of 1138 were diagnosed as a result of an invitation to the study (table 1) . Of these 896 men, 231 were detected at their fi rst screening visit and 665 during subsequent screening rounds. At the fi rst screening visit 3671 (48·4%) of 7578 had PSA below 1·00 ng/mL, 2960 (39·1%) of 7578 had a PSA between 1·00 and 2·99 ng/mL, and 947 (12·5%) of 7578 had a PSA of 3·00 ng/mL or greater; the risk of being diagnosed with prostate cancer during follow-up was 2·6%, 17·6%, and 45·5% respectively. The cumulative incidence of prostate cancer at 14 years was 12·7% in the screening group versus 8·2% in the control group (HR 1·64, 95% CI 1·50-1·80; p<0.0001; fi gure 2). During the fi rst year, after the start of screening, the HR was 5·2 (95% CI 3·1-8·6), which subsequently decreased to 3·7 (95% CI 2·2-6·2) at 1-2 years, 2·6 (95% CI 1·9--3·.6) at 2-4 years, 2·1 (95% CI 1·7-2·7) at 4-6 years, 1·7 (95% CI 1·3-2·1) at 6-8 years, and 1·2 (95% CI 1·0-1·3) at 8 years or more (fi gure 2).
Most of the prostate cancers diagnosed in the screening group were early-stage disease (table 2). The number of men with advanced prostate cancer (metastases or PSA >100 ng/mL at diagnosis) was lower in the screening group than in the control group (46 men vs 87; p=0·0003; table 2). Notably, in non-attendees in the screening group, a high proportion of cancers were advanced at diagnosis (table 2) .
The diff erence in stage distribution was mirrored by the treatment diff erence, with more hormonal therapy used in the control group than in the screening group and more surveillance or treatment with curative intent in the screening group than in the control group (table 3) . However, in men with low-and moderate-risk tumours, the proportion having curative treatment was similar between groups: 476 (49·2%) of 967 in the screening group and 228 (50·8%) of 448 in the control group. In the men diagnosed with prostate cancer, the median follow-up after diagnosis was 6·7 (IQR 3·1-9·5) years in the screening group and 4·3 (2·1-7·1) years in the control group. The COD committee and COD certifi cates were highly concordant in assessing whether the deaths *T1, not N1 or M1, and Gleason score ≤6 and prostate-specifi c antigen <10 ng/mL. †T1-2, but not N1 or M1, with a Gleason score ≤7, prostate-specifi c antigen <20 ng/mL or both; and not meeting the criteria for low risk. ‡T1-4, but not N1 or M1, with a Gleason score ≥8, prostate-specifi c antigen <100 ng/mL, or both; and not meeting the criteria for low or moderate risk. §N1 or M1, or prostate-specifi c antigen ≥100 ng/mL. ¶Includes seven cases detected at autopsy. The RR of dying from prostate cancer was 0·56 (95% CI 0·39-0·82; p=0·002) in the screening group compared with the control group (fi gure 3). The absolute cumulative-risk reduction (Kaplan-Meier estimates) of death from prostate cancer at 14 years was 0·40% (95% CI 0·17-0·64), from 0·90% in the control group to 0·50% in the screening group. A secondary analysis showed that the RR of death from prostate cancer for attendees compared with the control group was 0·44 (95% CI 0·28-0·68; p=0·0002) and the RR of death from prostate cancer for non-attendees compared with the control group was 1·05 (95% CI 0·62-1·78 p=0·84). The number of men with prostate cancer who died from unrelated causes was 109 (9·6%) of 1138 in the screening group and 54 (7·5%) of 718 in the control group. However, the follow-up time was longer for the men diagnosed with prostate cancer in the screening group than the control group (6·7 vs 4·3 years). Therefore, the cumulative risk (Kaplan-Meier estimates) of nonprostate cancer deaths measured from the date of prostate-cancer diagnosis was similar at 10 years, 13·1% in the screening group and 15·0% in the control group (log-rank test p=0·50).
The NNS to prevent one prostate-cancer death was 293 (95% CI 177-799), whereas the NNT was 12. If the calculations were restricted to attendees, the respective numbers were 234 (95% CI 154-492) and 15.
Discussion
The aim of this prospective, population-based randomised screening study was to assess the eff ectiveness of a screening programme in which men were fi rst randomised and then asked to participate. The design gives more representative results than does randomisation after informed consent, and mirrors the situation when screening is introduced in the population. The study yielded two major fi ndings. First, a PSA-based screening programme is acceptable to men aged 50 years or older, with 76% attending at least once. Second, with such a participation rate, a screening programme will decrease prostate-cancer mortality by as much as half over 14 years' follow-up.
Half of the attendees who died from prostate cancer were diagnosed at their fi rst screening visit and many of these men were 60 years of age or older at study entry. In a programme in which all men started screening at 50 years of age, some men could instead be diagnosed at a curable stage; therefore, potential for larger mortality reduction exists ( This study shows a much higher mortality reduction than in previous studies: an RR of 0·56 in this study compared with 0·80 in the ERSPC (0·84 if the Swedish cohort is withdrawn), 1 and no reduction in the PLCO study. Several factors might account for this. First, the men in our study were younger (median age 56 years at baseline) than in both previous publications (median age >60 years). Younger men are less likely than older men to have incurable prostate cancer at the fi rst screening and are therefore more likely to gain the full benefi t of screening. Second, the PSA threshold for biopsy was lower in our study than in most other ERSPC branches and in the PLCO trial. However, DRE was never used as a screening tool in our study, but was used by most ERSPC centres at the fi rst screening round and in the design of PLCO trial. Addition of DRE in our study might have resulted in an even larger mortality reduction than seen in our study, although only a few incurable cancers were found in men who attended the programme, and some of these incurable cancers were still non-palpable at diagnosis. 12 Third, the interval of screening in this study (every 2 years) was shorter than in the other ERSPC branches (every 4 years), although longer than in the PLCO trial (every year). Fourth, this study had a much higher rate of biopsy for men with a positive screening result (93% vs 30-40% in PLCO 19 ), a much lower rate of PSA testing before the start of the study (estimated as 3% vs 44% in PLCO), and probably a lower rate of contamination in the control group than in the PLCO trial. Fifth, the present study has much longer follow-up than do the ERSPC and PLCO studies (median 14 years from randomisation vs 9 years for ERSPC, 1 and 11·5 years for PLCO 7 ). Up to 10 years of follow-up, the Nelson-Aalen plot in our study resembles that which was published in the ERSPC study, suggesting that most of the benefi t from screening occurs after 10 years (fi gure 3). This is to be expected from a disease with long a lead-time and a long natural course. 20, 21 Although the median follow-up from randomisation is long, the follow-up time measured from prostate-cancer diagnosis is rather short; 6·7 years for attendees versus 4·3 years for controls in this study compared with 6·3 versus 5·2 years in the PLCO study. 7 The reasons as to why our study shows an important mortality reduction and the PLCO trial did not, despite a similar follow-up after diagnosis in the two studies, might in part be explained by the absence of pre-screening in our study, which meant many aggressive cancers were still detectable. Furthermore, contamination in the control group was low-at least during the fi rst 5 years of our study. An indication of these important diff erences is that despite the randomisation of 76 693 men in the PLCO trial versus 19 904 in our study, only 174 prostate-cancer deaths were recorded in the PLCO trial 7 compared with 122 in our study. The men in the PLCO trial were also older.
The RR of 0·56 within 14 years corresponds to an absolute risk reduction of 0·40% and no eff ect on overall mortality (similar number of men at risk at 14 years, [fi gure 3] and similar number of total deaths in the study group [table 4]). These low mortality fi gures are related to the young age of participants at the start of the study and the comparatively short follow-up after prostate-cancer diagnosis. Because about 5% of deaths among Swedish men are caused by prostate cancer, 22 it is obvious that we have so far studied only the early eff ects of screening. If the relative-risk reduction is sustained over time the mortality reduction, even measured in terms of absoluterisk reduction, might become important. An indication of this is the large diff erence between the arms in the number of men needing endocrine treatment-182 (1·8%) in the control group versus 103 (1·0%) in the screening group. The fact that 79 more men in the control group were treated with endocrine treatment than in the screening group might also be regarded as an important advantage. The increased ratio of unrelated deaths reported in the screening group compared with the control group (9·6% vs 7·5%) is explained by the longer follow-up of patients with prostate cancer in the screening group than in the control group, because there is no diff erence in non-prostate-cancer mortality if KaplanMeier estimates are calculated from diagnosis.
The high rate of attendance to this PSA-based screening programme is corroborated by fi ndings from several uncontrolled trials. Bartsch and co-workers 23 reported that 86·6% of men accepted an off er of a free PSA test and that 85·0% of those with raised PSA concentrations consented to additional urological assessment with prostate biopsies. 23 Moreover, all centres in the ERSPC study reported a high acceptance rate for screening. 1 The screening procedures with PSA testing and prostate biopsy are seldom associated with severe psychological distress, even for men with repeatedly raised PSA concentrations. 24, 25 We therefore conclude that acceptance is not an obstacle for a population-based prostate-cancerscreening programme. Diff erences between screening and control groups in cancer stage and grade show the cancer stage migration introduced by a PSA-based screening programme. Although 1·6 times as many prostate cancers were diagnosed in the screening group, the absolute number of patients with advanced disease was lower in the screening group than in the control group. Therefore, screening caused a true stage migration and resulted in a diff erent distribution of treatments between the two groups. However, in men with early cancer (low-and moderate-risk cancer), treatment with curative intent was as common in the control and screening groups (51% vs 49%), suggesting that the mortality diff erence resulted from screening and not from diff erent treatments.
At 14 years of follow-up, the number who needed to be invited to screening (corresponding to NNS) to prevent one prostate cancer death was 293, and the number who needed to be diagnosed (corresponding to NNT) was 12. These fi gures, and the RR of 0·56 in our study, can be compared with those of the commonly recommended practices of screening for breast and colon cancer. Because these fi gures are time-dependent, we focus this comparison on studies with similar follow-up periods. For mammography, a 2009 meta-analysis of randomised trials showed a number needed to invite to screening of 377 (credible interval 230-1050) for women aged 60-69 years and 1339 (credible interval 322-7455) for women aged 50-59 years, and RRs of 0·68 and 0·86 respectively at 11-20 years of follow-up. 5 Individual studies included in the meta-analysis, as well as other mammography studies, have shown similar numbers. 3, [26] [27] [28] [29] [30] [31] [32] [33] In a 2009 Cochrane review, the NNT for mammography was 10 over 10 years. 3 For colorectal-cancer screening by faecal occult-blood test, the RRs varied between 0·67 and 0·87 in four randomised trials [34] [35] [36] [37] and was 0·84 overall in both a 2008 Cochrane review 4 (after 11·7-18·4 years) and a meta-analysis by Towler and colleagues 6 (after 7·8-13·0 years). Towler and colleagues 6 estimated the NNS after 10 years to be 1173 (95% CI 741-2807). Moreover, a multicentre study has reported an RR of 0·69 for colorectal-cancer mortality, with fl exible-sigmoidoscopy screening for colorectal cancer, and an NNS of 489 at a median follow-up of 11·2 years. 38 The NNT cannot be calculated for comparison because screening for colorectal cancer is associated with a reduced colorectal-cancer incidence.
The NNT in our study is substantially lower than that in the ERSPC study, 1 which suggests that the NNT is very dependent on the length of follow-up. It is not easy to predict at which follow-up period the NNT will stabilise. Furthermore, since NNT in prostate-cancer screening mainly refl ects the risk of over-diagnosis, it is not easy at this point to make estimates of this risk but it is probably not as high as some have feared, 39 at least if screening is restricted to the age groups included in this study. As many as 314 (30%) screening attendees were in active surveillance at last follow-up in this study. The strategy of active surveillance will at least reduce the risk of overtreatment and the risk associated seems low. 40 Since the benefi t from prostate-cancer screening takes a long time to achieve-only marginal benefi ts are gained within the fi rst 10 years of starting prostate-cancer screening-one should be cautious to recommend that all elderly men have PSA screening. As the risk of overdiagnosis and over-treatment are still the major concerns in prostate-cancer screening, inviting men over the age of 70 for PSA screening seems questionable.
In summary, in this trial prostate-cancer screening was well accepted by the general population and can result in a relevant reduction in cancer mortality, greater than that reported in screening for breast or colorectal cancer. Nevertheless, PSA screening is associated with a long and varying lead time, resulting in a risk of over-diagnosis that is substantial but still of a largely unknown magnitude.
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